Previsioni di mercato dell\'epilessia nell\'Asia Pacifica fino al 2030 - Analisi regionale - per tipo (epilessia mioclonica progressiva, epilessia riflessa, epilessia generalizzata e altro), via di somministrazione (orale, parenterale e altri), tipo di trattamento (farmaci di prima generazione, farmaci di seconda generazione e farmaci di terza generazione), fascia d\'età (adulti e bambini) e canale di distribuzione (farmacie ospedaliere, farmacie al dettaglio e altri)
L\'aumento del programma di sensibilizzazione condotto dalle organizzazioni stimola il mercato dell\'epilessia nell\'area Asia-Pacifico
La crescente consapevolezza sull\'epilessia, sui suoi sintomi e sull\'importanza della diagnosi precoce ha portato a un aumento dei pazienti che cercano assistenza medica. Organizzazioni come l\'Epilepsy Foundation, l\'Epilepsy Society, l\'American Epilepsy Society e l\'Epilepsy Association of Central Florida svolgono un ruolo cruciale nell\'educazione delle persone su questa malattia. Il coinvolgimento di queste organizzazioni ha portato a un aumento dei tassi di diagnosi e a una popolazione di pazienti più ampia che necessita di cure per l\'epilessia. Numerose campagne di sensibilizzazione sono condotte da organizzazioni in tutto il mondo per diffondere la consapevolezza sulla condizione e sui trattamenti disponibili. Nel 2023, in occasione del Purple Day of Epilepsy, l\'Aster Prime Hospitals di Hyderabad (India), in collaborazione con la Walkers Association del Krishna Kant Park, ha organizzato un\'attività di sensibilizzazione. In totale, centocinquanta partecipanti, tra cui camminatori e praticanti di yoga, hanno preso parte a questa sessione. Inoltre, per migliorare la qualità della vita degli australiani affetti da epilessia, Epilepsy Action Australia offre una serie di strumenti e servizi volti a sensibilizzare, istruire e dotare gli individui delle competenze necessarie. Pertanto, tali iniziative e campagne di sensibilizzazione determinano un aumento delle diagnosi e dei trattamenti per l\'epilessia, offrendo opportunità di crescita redditizie al mercato.
Panoramica del mercato dell\'epilessia nell\'Asia Pacifica
Il mercato dell\'epilessia nell\'Asia Pacifica è analizzato in base a Cina, Giappone, India, Australia, Corea del Sud e resto dell\'Asia Pacifica. Secondo il rapporto dell\'Organizzazione mondiale della sanità (OMS), l\'epilessia è più comune nei paesi in via di sviluppo che nei paesi sviluppati, con una prevalenza rispettivamente del 6,1% e del 5,0%.
Entrate e previsioni del mercato dell\'epilessia nell\'Asia Pacifica fino al 2030 (milioni di $ USA)
Segmentazione del mercato dell\'epilessia nell\'Asia Pacifica
Il mercato dell\'epilessia nell\'Asia Pacifica è suddiviso in tipo, via di somministrazione, tipo di trattamento, fascia d\'età, canale di distribuzione e paese.
In base al tipo, il mercato dell\'epilessia nell\'Asia Pacifica è suddiviso in epilessia mioclonica progressiva, epilessia riflessa, epilessia generalizzata e altro. Il segmento dell\'epilessia generalizzata ha detenuto la quota di mercato maggiore nel 2022.
In termini di via di somministrazione, il mercato dell\'epilessia nell\'Asia Pacifica è suddiviso in orale, parenterale e altro. Il segmento orale ha detenuto la quota di mercato maggiore nel 2022.
In base al tipo di trattamento, il mercato dell\'epilessia nell\'Asia Pacifica è suddiviso in farmaci di prima generazione, farmaci di seconda generazione e farmaci di terza generazione. Il segmento dei farmaci di terza generazione ha detenuto la quota di mercato più ampia nel 2022.
In base alla fascia d\'età, il mercato dell\'epilessia dell\'Asia Pacifica è suddiviso in adulti e bambini. Il segmento degli adulti ha detenuto una quota di mercato maggiore nel 2022.
In termini di canale di distribuzione, il mercato dell\'epilessia dell\'Asia Pacifica è suddiviso in farmacie ospedaliere, farmacie al dettaglio e altri. Il segmento delle farmacie ospedaliere ha detenuto la quota di mercato più ampia nel 2022.
Per paese, il mercato dell\'epilessia dell\'Asia Pacifica è suddiviso in Cina, Giappone, India, Australia, Corea del Sud e resto dell\'Asia Pacifica. La Cina ha dominato la quota di mercato dell\'epilessia dell\'Asia Pacifica nel 2022.
Abbott Laboratories, Pfizer Inc, Eisai Co Ltd, UCB SA, LivaNova Plc, Novartis AG, Medtronic Plc, GSK Plc e H. Lundbeck AS sono alcune delle aziende leader che operano nel mercato dell\'epilessia dell\'Asia Pacifica.
TABLE OF CONTENTS
1. Introduction
1.1 The Insight Partners Research Report Guidance
1.2 Market Segmentation
2. Executive Summary
2.1 Key Insights
2.2 Market Attractiveness
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. Asia Pacific Pipeline Studies for Epilepsy Therapy Approaches
4.1 Pipeline Studies for Epilepsy Therapy Approaches
4.1.1 Cell and Gene Therapy Approaches
4.1.2 Encapsulated cell bio delivery (ECB) system
4.1.3 Gene Therapy for Epilepsy Clinical Overview
4.1.3.1 Genetic Therapies Adopted for Clinic Research of Epilepsy
4.1.3.1.1 Gene Supplementation - Overview
4.1.3.1.2 Gene Modulation - Overview
4.1.3.1.3 Antisense Oligonucleotides and RNA Interference - Overview
4.1.3.1.4 Neuropeptides - Overview
4.1.3.1.5 Engineered Channels - Overview
4.1.3.1.6 Endogenous Channels - Overview
4.1.3.2 Pipeline Studies of Viral Vectors for Epilepsy
4.1.3.3 Pipeline Studies of Non-Viral Vectors for Epilepsy
4.1.3.3.1 Polymer-based Non-Viral Vectors for Epilepsy
4.1.3.3.2 Lipid-based Non-Viral Vectors for Epilepsy
4.1.3.4 Adeno-Associated Virus (AAV)-Mediated Neuromodulatory Peptides - Overview
4.1.3.5 Neurotrophic Factors for Gene Therapy Approaches
4.1.3.6 Potassium Channels For Human Epileptic Phenotypes
4.1.3.7 Enzyme Inducing Antiepileptic Drugs
5. Asia Pacific Epilepsy Market - Key Market Dynamics
5.1 Market Drivers
5.1.1 Rising Prevalence of Epilepsy
5.1.2 Increasing Investments in Development of Epilepsy Therapies
5.2 Market Restraints
5.2.1 Recall of Products
5.3 Market Opportunities
5.3.1 Surge in Awareness Programs Conducted by Organizations
5.4 Future Trends
5.4.1 Gene Therapy as Promising Treatment Approach
5.5 Impact of Drivers and Restraints:
6. Epilepsy Market - Asia Pacific Analysis
6.1 Asia Pacific: Epilepsy Market
7. Asia Pacific Epilepsy Market Analysis - by Type
7.1 Overview
7.2 Progressive Myoclonic Epilepsy
7.2.1 Overview
7.2.2 Progressive Myoclonic Epilepsy: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
7.3 Reflex Epilepsy
7.3.1 Overview
7.3.2 Reflex Epilepsy: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
7.4 Generalized Epilepsy
7.4.1 Overview
7.4.2 Generalized Epilepsy: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
7.5 Other
7.5.1 Overview
7.5.2 Other: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
8. Asia Pacific Epilepsy Market Analysis - by Route of Administration
8.1 Overview
8.2 Oral
8.2.1 Overview
8.2.2 Oral: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
8.3 Parenteral
8.3.1 Overview
8.3.2 Parenteral: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
8.4 Others
8.4.1 Overview
8.4.2 Others: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
9. Asia Pacific Epilepsy Market Analysis - by Treatment Type
9.1 Overview
9.2 First Generation Drugs
9.2.1 Overview
9.2.2 First Generation Drugs: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
9.3 Second Generation Drugs
9.3.1 Overview
9.3.2 Second Generation Drugs: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
9.4 Third Generation Drugs
9.4.1 Overview
9.4.2 Third Generation Drugs: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
10. Asia Pacific Epilepsy Market Analysis - by Age Group
10.1 Overview
10.2 Adult
10.2.1 Overview
10.2.2 Adult: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
10.3 Children
10.3.1 Overview
10.3.2 Children: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
11. Asia Pacific Epilepsy Market Analysis - by Distribution Channel
11.1 Overview
11.2 Hospital Pharmacies
11.2.1 Overview
11.2.2 Hospital Pharmacies: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
11.3 Retail Pharmacies
11.3.1 Overview
11.3.2 Retail Pharmacies: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
11.4 Others
11.4.1 Overview
11.4.2 Others: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
12. Asia Pacific Epilepsy Market - Country Analysis
12.1 Asia Pacific Epilepsy Market Overview
12.1.1 Asia Pacific: Epilepsy Market Breakdown, by Key Country, 2022 and 2030 (%)
12.1.1.1 China: Epilepsy Market Overview
12.1.1.2 China: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
12.1.1.2.1 China: Epilepsy Market Breakdown, by Type
12.1.1.2.2 China: Epilepsy Market Breakdown, by Route of Administration
12.1.1.2.3 China: Epilepsy Market Breakdown, by Treatment Type
12.1.1.2.4 China: Epilepsy Market Breakdown, by Age Group
12.1.1.2.5 China: Epilepsy Market Breakdown, by Distribution Channel
12.1.1.3 Japan: Epilepsy Market Overview
12.1.1.4 Japan: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
12.1.1.4.1 Japan: Epilepsy Market Breakdown, by Type
12.1.1.4.2 Japan: Epilepsy Market Breakdown, by Route of Administration
12.1.1.4.3 Japan: Epilepsy Market Breakdown, by Treatment Type
12.1.1.4.4 Japan: Epilepsy Market Breakdown, by Age Group
12.1.1.4.5 Japan: Epilepsy Market Breakdown, by Distribution Channel
12.1.1.5 India: Epilepsy Market Overview
12.1.1.6 India: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
12.1.1.6.1 India: Epilepsy Market Breakdown, by Type
12.1.1.6.2 India: Epilepsy Market Breakdown, by Route of Administration
12.1.1.6.3 India: Epilepsy Market Breakdown, by Treatment Type
12.1.1.6.4 India: Epilepsy Market Breakdown, by Age Group
12.1.1.6.5 India: Epilepsy Market Breakdown, by Distribution Channel
12.1.1.7 Australia: Epilepsy Market Overview
12.1.1.8 Australia: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
12.1.1.8.1 Australia: Epilepsy Market Breakdown, by Type
12.1.1.8.2 Australia: Epilepsy Market Breakdown, by Route of Administration
12.1.1.8.3 Australia: Epilepsy Market Breakdown, by Treatment Type
12.1.1.8.4 Australia: Epilepsy Market Breakdown, by Age Group
12.1.1.8.5 Australia: Epilepsy Market Breakdown, by Distribution Channel
12.1.1.9 South Korea: Epilepsy Market Overview
12.1.1.10 South Korea: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
12.1.1.10.1 South Korea: Epilepsy Market Breakdown, by Type
12.1.1.10.2 South Korea: Epilepsy Market Breakdown, by Route of Administration
12.1.1.10.3 South Korea: Epilepsy Market Breakdown, by Treatment Type
12.1.1.10.4 South Korea: Epilepsy Market Breakdown, by Age Group
12.1.1.10.5 South Korea: Epilepsy Market Breakdown, by Distribution Channel
12.1.1.11 Rest of Asia Pacific: Epilepsy Market Overview
12.1.1.12 Rest of Asia Pacific: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
12.1.1.12.1 Rest of Asia Pacific: Epilepsy Market Breakdown, by Type
12.1.1.12.2 Rest of Asia Pacific: Epilepsy Market Breakdown, by Route of Administration
12.1.1.12.3 Rest of Asia Pacific: Epilepsy Market Breakdown, by Treatment Type
12.1.1.12.4 Rest of Asia Pacific: Epilepsy Market Breakdown, by Age Group
12.1.1.12.5 Rest of Asia Pacific: Epilepsy Market Breakdown, by Distribution Channel
13. Industry Landscape
13.1 Overview
13.2 Growth Strategies in Epilepsy Market
13.3 Organic Growth Strategies
13.3.1 Overview
13.4 Inorganic Growth Strategies
13.4.1 Overview
14. Company Profiles
14.1 Abbott Laboratories
14.1.1 Key Facts
14.1.2 Business Description
14.1.3 Products and Services
14.1.4 Financial Overview
14.1.5 SWOT Analysis
14.1.6 Key Developments
14.2 Pfizer Inc
14.2.1 Key Facts
14.2.2 Business Description
14.2.3 Products and Services
14.2.4 Financial Overview
14.2.5 SWOT Analysis
14.2.6 Key Developments
14.3 Eisai Co Ltd
14.3.1 Key Facts
14.3.2 Business Description
14.3.3 Products and Services
14.3.4 Financial Overview
14.3.5 SWOT Analysis
14.3.6 Key Developments
14.4 UCB SA
14.4.1 Key Facts
14.4.2 Business Description
14.4.3 Products and Services
14.4.4 Financial Overview
14.4.5 SWOT Analysis
14.4.6 Key Developments
14.5 LivaNova Plc
14.5.1 Key Facts
14.5.2 Business Description
14.5.3 Products and Services
14.5.4 Financial Overview
14.5.5 SWOT Analysis
14.5.6 Key Developments
14.6 Novartis AG
14.6.1 Key Facts
14.6.2 Business Description
14.6.3 Products and Services
14.6.4 Financial Overview
14.6.5 SWOT Analysis
14.6.6 Key Developments
14.7 Medtronic Plc
14.7.1 Key Facts
14.7.2 Business Description
14.7.3 Products and Services
14.7.4 Financial Overview
14.7.5 SWOT Analysis
14.7.6 Key Developments
14.8 GSK Plc
14.8.1 Key Facts
14.8.2 Business Description
14.8.3 Products and Services
14.8.4 Financial Overview
14.8.5 SWOT Analysis
14.8.6 Key Developments
14.9 H. Lundbeck AS
14.9.1 Key Facts
14.9.2 Business Description
14.9.3 Products and Services
14.9.4 Financial Overview
14.9.5 SWOT Analysis
14.9.6 Key Developments
15. Appendix
15.1 About The Insight Partners
?
List of Tables
Table 1. Asia Pacific Epilepsy Market Segmentation
Table 2. Cell Therapy Approach - An Overview
Table 3. Gene Therapy Approach - An Overview
Table 4. Encapsulated cell bio delivery (ECB) system Cell and Gene Therapy Approach - An Overview
Table 5. Preclinically Tested Genetic Therapies for Epilepsy
Table 6. Clinical Trials for Epilepsy Gene Therapy: Overview
Table 7. Viral Vectors Comparison with respect to Various Parameters
Table 8. Subfamilies of Human K+ Channels Involved in Epilepsies
Table 9. Enzyme-Inducing Antiepileptic Drugs
Table 10. Enzyme-Inducing Antiepileptic Drugs & Drug Targets Types Overview
Table 11. China: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Type
Table 12. China: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Route of Administration
Table 13. China: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Treatment Type
Table 14. China: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Age Group
Table 15. China: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Distribution Channel
Table 16. Japan: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Type
Table 17. Japan: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Route of Administration
Table 18. Japan: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Treatment Type
Table 19. Japan: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Age Group
Table 20. Japan: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Distribution Channel
Table 21. India: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Type
Table 22. India: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Route of Administration
Table 23. India: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Treatment Type
Table 24. India: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Age Group
Table 25. India: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Distribution Channel
Table 26. Australia: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Type
Table 27. Australia: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Route of Administration
Table 28. Australia: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Treatment Type
Table 29. Australia: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Age Group
Table 30. Australia: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Distribution Channel
Table 31. South Korea: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Type
Table 32. South Korea: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Route of Administration
Table 33. South Korea: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Treatment Type
Table 34. South Korea: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Age Group
Table 35. South Korea: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Distribution Channel
Table 36. Rest of Asia Pacific: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Type
Table 37. Rest of Asia Pacific: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Route of Administration
Table 38. Rest of Asia Pacific: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Treatment Type
Table 39. Rest of Asia Pacific: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Age Group
Table 40. Rest of Asia Pacific: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Distribution Channel
Table 41. Recent Organic Growth Strategies in Epilepsy Market
Table 42. Recent Inorganic Growth Strategies in the Epilepsy Market
?
List of Figures
Figure 1. Asia Pacific Epilepsy Market Segmentation, by Country
Figure 2. Epilepsy Market - Key Market Dynamics
Figure 3. Impact Analysis of Drivers and Restraints
Figure 4. Epilepsy Market Revenue (US$ Million), 2020-2030
Figure 5. Epilepsy Market Share (%) - by Type (2022 and 2030)
Figure 6. Progressive Myoclonic Epilepsy: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
Figure 7. Reflex Epilepsy: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
Figure 8. Generalized Epilepsy: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
Figure 9. Other: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
Figure 10. Epilepsy Market Share (%) - by Route of Administration (2022 and 2030)
Figure 11. Oral: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
Figure 12. Parenteral: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
Figure 13. Others: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
Figure 14. Epilepsy Market Share (%) - by Treatment Type (2022 and 2030)
Figure 15. First Generation Drugs: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
Figure 16. Second Generation Drugs: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
Figure 17. Third Generation Drugs: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
Figure 18. Epilepsy Market Share (%) - by Age Group (2022 and 2030)
Figure 19. Adult: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
Figure 20. Children: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
Figure 21. Epilepsy Market Share (%) - by Distribution Channel (2022 and 2030)
Figure 22. Hospital Pharmacies: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
Figure 23. Retail Pharmacies: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
Figure 24. Others: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
Figure 25. Asia Pacific: Epilepsy Market, by Key Country - Revenue (2022) (US$ Million)
Figure 26. Asia Pacific: Epilepsy Market Breakdown, by Key Countries, 2022 and 2030 (%)
Figure 27. China: Epilepsy Market - Revenue and Forecast to 2030(US$ Million)
Figure 28. Japan: Epilepsy Market - Revenue and Forecast to 2030(US$ Million)
Figure 29. India: Epilepsy Market - Revenue and Forecast to 2030(US$ Million)
Figure 30. Australia: Epilepsy Market - Revenue and Forecast to 2030(US$ Million)
Figure 31. South Korea: Epilepsy Market - Revenue and Forecast to 2030(US$ Million)
Figure 32. Rest of Asia Pacific: Epilepsy Market - Revenue and Forecast to 2030(US$ Million)
Figure 33. Growth Strategies in Epilepsy Market
- Abbott Laboratories
- Pfizer Inc
- Eisai Co Ltd
- UCB SA
- LivaNova Plc
- Novartis AG
- Medtronic Plc
- GSK Plc
- H. Lundbeck AS
- Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the Asia Pacific epilepsy market.
- Highlights key business priorities in order to assist companies to realign their business strategies.
- The key findings and recommendations highlight crucial progressive industry trends in the Asia Pacific epilepsy market, thereby allowing players across the value chain to develop effective long-term strategies.
- Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
- Scrutinize in-depth Asia Pacific market trends and outlook coupled with the factors driving the Asia Pacific epilepsy market, as well as those hindering it.
- Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution.